Analysis of the Therapeutic Efficacy and Safety of Abiraterone in the Treatment of Metastatic Hormone Sensitive Prostate Cancer
Wang Shanshan
Tang Jiahong
Abstract：Objective:To investigate the efficacy and safety of abiraterone acetate in the treatment of metastatic hormone-sensitive prostate cancer(mHSPC).Methods:A retrospective study was conducted on 90 patients with mHSPC who were treated in the hospital from January 2020 to December 2023.They were divided into control group and observation group,with 45 patients in each group based on different treatment plans.The control group received conventional treatment,while the observation group received abiraterone treatment on top of that.Statistical comparison was conducted between the two groups in terms of clinical efficacy,prostate specific antigen(PSA)response rate,and pain severity before and after treatment[visual analog scale(VAS),simplified McGill pain questionnaire(SF-MPQ)],quality of life[extended prostate cancer composite index(EPIC)],tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragment 21-1(CYFRA21-1),neuron-specific enolase(NSE)],immune function(CD3+,CD4+and CD4+/CD8+)factors related to disease progression[human kallikrein 2(hk2),nuclear factor kappa B(NF-κB)].The adverse reactions and survival time of the two groups were compared.Results:The total effective rate and the incidence of PSA reaction in the observation group were higher than those in the control group,and the differences were statistically significant(x2=6.667,4.500;P＜0.05).After treatment,the VAS score and SF-MPQ score of patients in the observation group were lower than those in the control group,and the EPIC scores of patients in the observation group were higher than those in the control group.The differences were statistically significant(t=11.522,8.002,12.361,10.290,9.987,6.308;P＜0.001).After treatment,the levels of serum CEA,CYFRA21-1 and NSE in the observation group were lower than those in the control group,and the differences were statistically significant(t=16.079,14.245,9.819;P＜0.001).After treatment,the levels of CD3+,CD4+,and CD4+/CD8+in the observation group were higher than those in the control group,and the differences were statistically significant(t=7.146,7.145,5.336;P＜0.001).After treatment,the levels of serum hk2 and NF-κB in the observation group were lower than those in the control group,and the differences were statistically significant(t=17.082,8.515;P＜0.001).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(x2=0.241,P＞0.05).The overall survival time of patients in the observation group was longer than that in the control group,and the difference was statistically significant(Z=15.263,P＜0.001).Conclusion:The efficacy of abiraterone in the treatment of mHSPC is well established and has certain safety,which can improve the PSA response rate,reduce pain levels,improve quality of life,reduce immunosuppression,and prolong survival time,with certain safety
Keywords：Prostate cancerHormone sensitivityMetastaticAbitheronTherapeutic efficacy
Publication Date：2025-08-10
Online Publishing Date：2025-09-10(First online date of this platform, not the publication date of the document)
Pages：4( 1852-1855 )